Sedana Medical reaches an important milestone – The first patient in Asia is treated with AnaConDa.
Sedana Medical AB’s (“Sedana Medical”) product AnaConDa is used in South Korea and Asia for the first time. South Korea is the first country in Asia to approve, launch and use AnaConDa for inhalation sedation of mechanically ventilated patients in intensive care units.
AnaConDa received approval from the South Korean authority K-FDA earlier in 2017, making South Korea the first market in Asia to approve the AnaConDa technology. Sedana Medical had previously signed an exclusive contract with the South Korean distributor DaeSeuk Med Co. Ltd. concerning the rights to market and sell AnaConDa to South Korean hospitals. DaeSeuk has a nationwide sales force which has started to train the health service in using Sedana Medical’s patented innovation AnaConDa.
The AnaConDa medical device enables inhalation sedation of patients in intensive care units in an easy to use and safe manner and signifies a paradigm shift in the treatment of severely ill mechanically ventilated patients in intensive care units.
“Though the treatment of the first patient with AnaConDa for inhalation sedation in South Korea, we have established a presence in our first Asian market. This represents a milestone in the company's history and is in line with our strategy. South Korea is also an important reference country for further registrations of AnaConDa in other Asian markets. As a result we have taken another step towards realising our vision of making inhalation sedation with IsoConDa and AnaConDa a global standard method for the sedation of mechanically ventilated patients in intensive care,” says Christer Ahlberg, CEO of Sedana Medical AB (publ).
The market in brief
Sedana Medical's market consists primarily of mechanically ventilated intensive care patients. The market for sedation of mechanically ventilated intensive care patients today consists of established drugs that are administered intravenously. The target group the Company is focusing on are those patients who are ventilated for more than 24 hours, a target group that globally amounts to between two and four million patients per year. In total, the Company consider this to be a market of SEK 10-20 billion per year, of which Europe accounts for about SEK 6 billion.
For additional information, please contact:
Christer Ahlberg, CEO, Sedana Medical AB
Mobile: +46 70 675 33 30, E-mail: Christer.email@example.com
Pareto Securities is certified advisor to Sedana Medical.
This information is such that Sedana Medical AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on 6 July 2017 at 17.10 p.m. (CET).
Sedana Medical AB (publ) is a Swedish company that develops, manufactures and sells the medical device AnaConDa. AnaConDa is a medical device for inhalation sedation of mechanically ventilated patients in intensive care units. At the end of 2016, the company initiated a major clinical study to receive market approval in Europe for IsoConDa (isoflurane) for inhalation sedation in intensive care units. The study is expected to end in late 2018. Registration is expected at the end of 2019. Sedana Medical has sales offices in Germany, Spain and France, as well as external distributors in Europe, the Middle East, Canada, Australia and South Korea. The headquarters is based in Danderyd, Sweden and the company has R&D operations in Ireland.